金陵药业
(000919)
| 流通市值：40.79亿 | | | 总市值：40.80亿 |
| 流通股本：6.22亿 | | | 总股本：6.22亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 768,671,414.38 | 3,197,324,288.02 | 2,380,142,974.77 | 1,601,071,008.21 |
| 营业收入 | 768,671,414.38 | 3,197,324,288.02 | 2,380,142,974.77 | 1,601,071,008.21 |
| 二、营业总成本 | 747,885,190.74 | 3,159,275,152.03 | 2,318,855,766.79 | 1,565,898,002.66 |
| 营业成本 | 603,324,751.58 | 2,530,344,522.93 | 1,888,611,372.57 | 1,289,905,608.04 |
| 税金及附加 | 4,675,566.86 | 22,999,146.56 | 15,752,595.26 | 10,064,279.06 |
| 销售费用 | 25,803,258.94 | 139,244,748.49 | 74,902,085.72 | 41,514,693.21 |
| 管理费用 | 89,193,023.54 | 368,613,146.96 | 271,433,388.73 | 183,261,110.04 |
| 研发费用 | 25,884,152.17 | 110,135,232.37 | 75,136,411.86 | 45,341,568.66 |
| 财务费用 | -995,562.35 | -12,061,645.28 | -6,980,087.35 | -4,189,256.35 |
| 其中:利息费用 | 1,237,644.89 | 5,211,346.89 | 3,844,437.9 | 2,574,532.95 |
| 其中:利息收入 | 2,361,712.8 | 19,188,199.53 | 11,609,053.76 | 7,243,139.14 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | 2,785,169.21 | -108,568.42 | 10,178,587.88 | 12,013,263.09 |
| 加:投资收益 | 3,820,402.61 | 30,195,899.89 | 13,521,245.87 | 11,824,341.53 |
| 资产处置收益 | 4,908,344.96 | -387,493.74 | -42,789.62 | -44,966.62 |
| 资产减值损失(新) | 0 | -19,065,018.29 | 0 | 0 |
| 信用减值损失(新) | 295,342.39 | 10,316,551.98 | -1,812,715.63 | -1,901,062.12 |
| 其他收益 | 2,473,704.22 | 10,238,408.92 | 6,471,274.5 | 3,425,735.47 |
| 四、营业利润 | 35,069,187.03 | 69,238,916.33 | 89,602,810.98 | 60,490,316.9 |
| 加:营业外收入 | 273,330.33 | 1,470,471.88 | 829,901.43 | 720,443.13 |
| 减:营业外支出 | 421,954 | 5,518,072.43 | 721,568.38 | 221,742.26 |
| 五、利润总额 | 34,920,563.36 | 65,191,315.78 | 89,711,144.03 | 60,989,017.77 |
| 减:所得税费用 | 5,277,918.44 | 13,899,029.82 | 14,892,864.4 | 10,572,092.45 |
| 六、净利润 | 29,642,644.92 | 51,292,285.96 | 74,818,279.63 | 50,416,925.32 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | 29,642,644.92 | 51,292,285.96 | 74,818,279.63 | 50,416,925.32 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | 28,003,133.19 | 53,914,615.13 | 68,458,333.52 | 48,333,532.45 |
| 少数股东损益 | 1,639,511.73 | -2,622,329.17 | 6,359,946.11 | 2,083,392.87 |
| 扣除非经常损益后的净利润 | 19,261,963.84 | 35,004,944.71 | 56,644,232.75 | 35,510,166.16 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | 0.05 | 0.09 | 0.11 | 0.08 |
| (二)稀释每股收益 | 0.05 | 0.09 | 0.11 | 0.08 |
| 八、其他综合收益 | 0 | -75,520.53 | -75,520.53 | 0 |
| 归属于母公司股东的其他综合收益 | 0 | -41,196.45 | -41,196.45 | 0 |
| 九、综合收益总额 | 29,642,644.92 | 51,216,765.43 | 74,742,759.1 | 50,416,925.32 |
| 归属于母公司股东的综合收益总额 | 28,003,133.19 | 53,873,418.68 | 68,417,137.07 | 48,333,532.45 |
| 归属于少数股东的综合收益总额 | 1,639,511.73 | -2,656,653.25 | 6,325,622.03 | 2,083,392.87 |
| 公告日期 | 2026-04-28 | 2026-03-31 | 2025-10-28 | 2025-08-28 |
| 审计意见(境内) | | 标准无保留意见 | | |